THERAVANCE BIOPHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
THERAVANCE BIOPHARMA INC. - More news...
THERAVANCE BIOPHARMA INC. - More news...
- Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
- Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
- Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
- Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
- Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
- Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
- Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
- Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
